VJOncology Podcast

Latest Episodes:

Latest developments in immunotherapy for patients with melanoma Jul 01, 2021

Show notes

Surgery is an effective treatment for non-metastatic melanoma, however, advanced melanoma demands additional intervention, such as chemotherapy or immunotherapy. The development of immunotherapies for melanoma has significantly improved outcomes for patients with metastatic cancer. Several immunotherapies for metastatic melanoma have already received FDA approval, including nivolumab and ipilimumab, and research is ongoing to develop new combination regimens to improve treatment safety and efficacy.

In this podcast, Evan J. Lipson, MD, of the John Hopkins Medical Institute in Baltimore, James Larkin, PhD, FRCP, of The Royal Marsden NHS Foundation Trust in London, and Omid Hamid, MD, of The Angeles Clinic and Research Institute in Los Angeles, discuss key updates on immunotherapies for the treatment of melanoma, as presented at the 2021 ASCO Virtual Meeting.

The post Latest developments in immunotherapy for patients with melanoma appeared first on VJOncology.

ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer Jun 25, 2021

Show notes

Prostate-specific membrane antigen (PSMA) is overexpressed in more than 80% of prostate cancer tumors, making it a promising diagnostic and therapeutic target. Given the highly limited expression of PSMA outside of the prostate, precision approaches that specifically target PSMA have been of substantial interest in the field.

PSMA-targeted radionuclide therapy combines a PSMA ligand with a radioactive compound that inhibits tumor cell growth and replication through induction of DNA damage. Early data assessing radiolabeled monoclonal antibodies against PSMA demonstrated some efficacy against prostate tumors but were hindered by poor tumor permeability and slow blood clearance. More recent investigations have assessed radiolabeled small molecules that show more promise. Evidence to date highlights radionuclide therapy as an exciting new option for metastatic castration-resistant prostate cancer, an area of high unmet need for new targeted treatment options.

In this deep dive into the latest in PSMA-targeted radionuclide therapy, Karim Fizazi, MD, PhD, Institut Gustave Roussy, and Scott Tagawa, MD, MS, Weill Cornell Medical College, discuss results from the VISION trial of 177Lu-PSMA-617 and a Phase I/II study of 225Ac-J591, as well as the future of PSMA-targeted agents and important unanswered questions.

The post ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer appeared first on VJOncology.

The Lung Cancer Sessions: Highlights from BTOG 2021 Jun 22, 2021

Show notes

VJOncology has assembled a panel of leading experts, who offer their perspectives on the latest developments in lung cancer presented at the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

In this podcast, Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust London, UK, is joined by Samreen Ahmed, MBBS, MSc(onc), FRCP, MD, University Hospitals of Leicester Trust, Leicester, UK, David Gilligan, MBChB, FRCPE, FRCR, Addenbrooke’s & Papworth Hospitals, Cambridge, UK and Neal Navani, MBBS, PhD, University College London Hospitals NHS Foundation Trust, London, UK.

Tune in to hear the expert panel discuss the key learnings from the 19th BTOG Annual Conference, as they offer their perspectives on the impact of the COVID-19 pandemic on lung cancer care and managing patients with malignant pleural effusions. The panel also discusses the latest developments in novel KRAS inhibitors and antibody-drug conjugates (ADCs), radiotherapy in the adjuvant setting and the role of neoadjuvant checkpoint inhibitor therapies.

The post The Lung Cancer Sessions: Highlights from BTOG 2021 appeared first on VJOncology.

ESMO Breast 2021: updates on immunotherapy Jun 10, 2021

Show notes

Breast cancer is the most common type of cancer in women. Although most cases of early-stage non-metastatic disease are curable with surgery, effective treatments for later-stage and metastatic disease remain an unmet need. Several immunotherapies have received FDA approval for the treatment of breast cancer, including pembrolizumab, atezolizumab and trastuzumab deruxtecan.

In this podcast, Rebecca Dent, MD, FRCP, of the National Cancer Centre Singapore, Rupert Bartsch, MD, of the Medical University of Vienna in Austria, and Marleen Kok, MD, PhD, of the Netherlands Cancer Institute in Amsterdam, discuss key updates on immunotherapies for the treatment of breast cancer, as presented at the 2021 ESMO Breast Cancer Virtual Meeting.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post ESMO Breast 2021: updates on immunotherapy appeared first on VJOncology.

The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO GU 2021 May 14, 2021

Show notes

VJOncology has assembled a panel of leading experts, who offer their perspectives on the latest bladder and kidney cancer data presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, which was held virtually in February 2021.

In this podcast, Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, is joined by Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, Andrea Apollo, MD, National Cancer Institute, Bethesda, MD, and Thomas Powles, MBBS, MRCP, Barts Cancer Institute, London, UK.

Tune in to learn more about the latest clinical trial data in genitourinary cancer, including updates from EV-301, evaluating enfortumab vedotin versus chemotherapy in patients with urothelial cancer, and CheckMate 274, studying adjuvant nivolumab for high-risk bladder cancer patients. The panel also discuss findings from the POUT trial for perioperative chemotherapy in upper tract urothelial cancer and investigations into combinations of cabozantinib, nivolumab and ipilimumab in all GU tumors. The panel share their insights on these exciting trial updates and debate how these advances will translate into multidisciplinary care for patients with genitourinary cancers.

The post The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO GU 2021 appeared first on VJOncology.

Sequencing HER2-targeting therapies in the metastatic breast cancer space May 14, 2021

Show notes

Treatment approaches in breast cancer are multimodal, and with the onset of novel immunotherapies and targeted agents, the therapeutic landscape of patients with advanced disease has expanded. In HER2+ disease, the treatment landscape has become saturated with novel HER2-targeting agents, bringing into question how these agents should be sequenced for maximum benefit to patients.

In this podcast, we spoke with three leading experts in breast cancer who discuss the optimal sequencing of HER2-targeted therapies such as T-DM1, neratinib, tucatinib, and margetuximab. Join Lisa Carey, MD, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France, who outline decision making in the metastatic HER2+ breast cancer space, as well as how to sequence these novel agents.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post Sequencing HER2-targeting therapies in the metastatic breast cancer space appeared first on VJOncology.

Latest news in GU: CAR-T in RCC, updates from IMvigor130, & liquid biopsies in prostate cancer May 13, 2021

Show notes

The American Association for Cancer Research Annual Meeting 2021 (AACR) took place virtually this year and showcased an array across the spectrum of cancer research, from cancer biology to translational studies and trial updates.

In this podcast, we hear from three leading experts in genitourinary cancer and their insights from the AACR annual meeting. Yufei Wang, PhD, Dana-Farber Cancer Institute, Boston, MA, Enrique Grande, MD, of the MD Anderson Cancer Center Madrid, Madrid, Spain, and, Arpit Rao, MD, University of Minnesota, Minnesota, MN, talk on the development of a dual-targeted CAR T-cell evaluated in clear cell renal cell carcinoma, the latest overall survival data from IMvigor130 (NCT02807636), investigating atezolizumab in untreated metastatic urothelial carcinoma, and the clinical utility of liquid biopsies in prostate cancer.

This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

The post Latest news in GU: CAR-T in RCC, updates from IMvigor130, & liquid biopsies in prostate cancer appeared first on VJOncology.

The GU Sessions: Prostate Cancer Highlights from ASCO GU 2021 May 13, 2021

Show notes

The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium showcased a range of exciting clinical trial data and major milestones in prostate cancer. VJOncology has bought together a team of leading experts in prostate cancer to explore their insights on key updates from this meeting.

In this exclusive podcast, Neal Shore, MD, FACS, Carolina Urologic Research Center, SC was joined by Bertrand Tombal, MD, PhD, Cliniques Universataires Saint-Luc, Brussels, Belgium, Rana McKay, MD, UC San Diego Health, CA, and Robert Jones, MBChB, PhD, University of Glasgow & Beaston West of Scotland Cancer Center, Glasgow, UK.

The panel engage in an insightful discussion on the updated results from the ACIS trial in metastatic CRPC, as well as final analyses of the landmark Phase III SPARTAN, PROSPER and ARAMIS studies in non-metastatic CRPC. In addition, the panel debate the findings from the Phase III PROfound trial evaluating the PARP inhibitor olaparib and offer their perspectives on GnRH receptor antagonists, PSMA-PET and the integration of genomic profiling into practice.

The post The GU Sessions: Prostate Cancer Highlights from ASCO GU 2021 appeared first on VJOncology.

BTOG 2021: KRAS targeting and oncogenically-driven lung cancer May 12, 2021

Show notes

Traditional treatments for lung cancer include chemotherapy, radiotherapy and surgery, however the identification of oncogenic drivers, such as EGFR, ALK and ROS1, offers the potential for novel targeted therapies and personalized approaches to lung cancer treatment. Numerous studies and trials are underway which are investigating therapies targeting oncogenes including KRAS, PD-1/PD-L1 and JAK2, however, targeting of these genes and pathways has presented many challenges.

In this podcast Colin Lindsay, BSc, MBChB, MRCP, PhD, of the Christie NHS Foundation Trust, Manchester, UK, and Samreen Ahmed, FRCP, MD, of University Hospitals of Leicester, Leicester, UK, discuss the history of KRAS-targeting and the latest updates in the treatment of oncogenically-driven lung cancer, as presented at the British Thoracic Oncology Group’s 19th Annual Conference, which took place virtually.

The post BTOG 2021: KRAS targeting and oncogenically-driven lung cancer appeared first on VJOncology.

The Breast Cancer Sessions: a focus on the St. Gallen Consensus Apr 26, 2021

Show notes

At the 17^th St. Gallen International Breast Cancer Conference 2021, leading experts gathered virtually to take part in the renowned St. Gallen International Consensus Session on the optimal treatment of early breast cancer.

In this podcast, St. Gallen Consensus Session Co-Chair Giuseppe Curigliano, MD, PhD, European Institute of Oncology & University of Milan, Milan, Italy, is joined by consensus panelists Lisa Carey, MD, FASCO, The University of North Carolina at Chapel Hill, NC, Hope Rugo, MD, FASCO, University of California, San Francisco, CA, and Fatima Cardoso, MD, Champalimaud Clinical Center, Lisbon, Portugal.

Tune in to hear the expert panel discuss the key takeaways from the consensus session and the remaining challenges in early breast cancer care. They offer their perspectives on the role of pathologic complete response (pCR) in the post-neoadjuvant setting, gene signature assays for chemotherapy in pre- and post-menopausal women, neoadjuvant treatment in triple-negative and HER2-positive breast cancer, as well as the role of CDK4/6 inhibitors in the adjuvant setting.

The post The Breast Cancer Sessions: a focus on the St. Gallen Consensus appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected